Michael R. Fetell

2.8k total citations
47 papers, 2.0k citations indexed

About

Michael R. Fetell is a scholar working on Genetics, Molecular Biology and Neurology. According to data from OpenAlex, Michael R. Fetell has authored 47 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Genetics, 12 papers in Molecular Biology and 11 papers in Neurology. Recurrent topics in Michael R. Fetell's work include Glioma Diagnosis and Treatment (17 papers), Brain Metastases and Treatment (6 papers) and CNS Lymphoma Diagnosis and Treatment (5 papers). Michael R. Fetell is often cited by papers focused on Glioma Diagnosis and Treatment (17 papers), Brain Metastases and Treatment (6 papers) and CNS Lymphoma Diagnosis and Treatment (5 papers). Michael R. Fetell collaborates with scholars based in United States, Canada and United Kingdom. Michael R. Fetell's co-authors include Casilda Balmaceda, Lewis P. Rowland, Jerome Engel, Jeffrey N. Bruce, Michael B. Sisti, Fred H. Hochberg, Bennett M. Stein, Arthur P. Hays, Charles Hesdorffer and Michael D. Prados and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michael R. Fetell

47 papers receiving 1.9k citations

Peers

Countries citing papers authored by Michael R. Fetell

Since Specialization

Citations

This map shows the geographic impact of Michael R. Fetell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael R. Fetell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael R. Fetell more than expected).

Fields of papers citing papers by Michael R. Fetell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael R. Fetell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael R. Fetell. The network helps show where Michael R. Fetell may publish in the future.

Co-authorship network of co-authors of Michael R. Fetell

This figure shows the co-authorship network connecting the top 25 collaborators of Michael R. Fetell. A scholar is included among the top collaborators of Michael R. Fetell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael R. Fetell. Michael R. Fetell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of fasinumab in an NSAID-controlled study in patients with pain due to osteoarthritis of the knee or hip 2025 ·BMC Musculoskeletal Disorders ·Stephen J. DiMartino, Haitao Gao, (unknown), Guillermo J. Valenzuela, Thomas Fuerst, Chetachi A. Emeremni, (unknown), Hazem E. Hassan, K. C. Turner, John D. Davis, Souhil Zaim, Jesse T. Chao, (unknown), (unknown), (unknown), (unknown), Michael R. Fetell, (unknown), Gregory P. Geba, Paula Dakin	1
2	A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hip 2024 ·SHILAP Revista de lepidopterología ·Stephen J. DiMartino, (unknown), Thomas J. Schnitzer, Haitao Gao, (unknown), (unknown), (unknown), K. C. Turner, Hazem E. Hassan, (unknown), John D. Davis, (unknown), (unknown), (unknown), Michael R. Fetell, (unknown), Gregory P. Geba, Paula Dakin	2
3	Cutaneous nerve fiber and peripheral Nav1.7 assessment in a large cohort of patients with postherpetic neuralgia 2023 ·Pain ·Michael R. Fetell, (unknown), Thomas Li, (unknown), Jan Vollert, (unknown), (unknown), (unknown), Phillip J. Albrecht, Frank L. Rice, Ralf Baron	7
4	Talampanel suppresses the acute and chronic effects of seizures in a rodent neonatal seizure model 2009 ·Epilepsia ·Paven K. Aujla, Michael R. Fetell, Frances E. Jensen	33
5	Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours 2007 ·Cancer Chemotherapy and Pharmacology ·Stephan A. Veltkamp, Hilde Rosing, Alwin D. R. Huitema, Michael R. Fetell, (unknown), Jos H. Beijnen, Jan H.M. Schellens	17
6	Randomized Study of Paclitaxel and Tamoxifen Deposition into Human Brain Tumors: Implications for the Treatment of Metastatic Brain Tumors 2006 ·Clinical Cancer Research ·Robert L. Fine, Johnson Chen, Casilda Balmaceda, Jeffrey N. Bruce, (unknown), Manisha Desai, Michael B. Sisti, Guy M. McKhann, Robert Goodman, Joseph Bertino, Anne N. Nafziger, Michael R. Fetell	55
7	A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 incombination with carboplatin administered intravenously for the treatment ofrecurrent malignant glioma 2003 ·Neuro-Oncology ·Michael D. Prados, S. Clifford Schold, Howard A. Fine, Kurt A. Jaeckle, Fred H. Hochberg, László Mechtler, Michael R. Fetell, Surasak Phuphanich, Lynn G. Feun, Todd J. Janus, Kathleen Ford, (unknown)	160
8	A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma 2003 ·Neuro-Oncology ·Michael D. Prados, S. Clifford Schold, Howard A. Fine, Kurt A. Jaeckle, Fred H. Hochberg, Laszlo Mechtler, Michael R. Fetell, Surasak Phuphanich, Lynn G. Feun, Todd J. Janus, Kathleen Ford, (unknown)	8
9	Supratentorial Ependymomas in Adult Patients 1999 ·Neurosurgery ·Theodore H. Schwartz, Samuel Kim, (unknown), Emilia Bagiella, Casilda Balmaceda, Michael R. Fetell, Bennett M. Stein, Michael B. Sisti, Jeffrey N. Bruce	84
10	A Phase I Study of High-dose BCNU, Etoposide and Escalating-dose Thiotepa (BTE) with Hematopoietic Progenitor Cell Support in Adults with Recurrent and High-risk Brain Tumors 1999 ·Journal of Neuro-Oncology ·Kyriakos P. Papadopoulos, Casilda Balmaceda, Michael R. Fetell, Elizabeth Kaufman, Linda T. Vahdat, Jeffrey N. Bruce, Michael B. Sisti, Steven R. Isaacson, (unknown), David G. Savage, Andrea B. Troxel, Karen H. Antman, Charles S. Hesdorffer	8
11	Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. 1998 ·Journal of Clinical Oncology ·Charles Hesdorffer, Janet Ayello, Maureen Ward, Andreas Kaubisch, Linda T. Vahdat, Casilda Balmaceda, T. J. Garrett, Michael R. Fetell, (unknown), A Bank, Karen H. Antman	164
12	High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults 1998 ·Bone Marrow Transplantation ·(unknown), (unknown), Michael R. Fetell, Linda T. Vahdat, T. J. Garrett, (unknown), Casilda Balmaceda, Jeffrey N. Bruce, Michael B. Sisti, Steven R. Isaacson, (unknown), R. Hawks, Emilia Bagiella, (unknown), (unknown)	13
13	Thiotepa and etoposide treatment of recurrent malignant gliomas: phase I study 1997 ·Cancer Chemotherapy and Pharmacology ·Casilda Balmaceda, Michael R. Fetell, Charles Hesdorffer	7
14	Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. 1997 ·Journal of Clinical Oncology ·Michael R. Fetell, Stuart A. Grossman, Joanne Fisher, Bernard F. Erlanger, Eric K. Rowinsky, (unknown), Steven Piantadosi	141
15	Reversible dementia due to macroprolactinoma 1993 ·Journal of neurosurgery ·Michael H. Brisman, Michael R. Fetell, Kalmon D. Post	19
16	Induction of growth suppression and modification of gene expression in multi‐drug‐resistant human glioblastoma multiforme cells by recombinant human fibroblast and immune interferon 1992 ·International Journal of Cancer ·Thomas Moulton, Hongping Jiang, Ludovico Guarini, Michael R. Fetell, Paul B. Fisher	5
17	Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study. 1991 ·Journal of Clinical Oncology ·W.K. Alfred Yung, Michael D. Prados, Victor A. Levin, Michael R. Fetell, (unknown), M. S. Mahaley, Michael Salcman, Erlinda Etcubanas	71
18	Lymphoma, motor neuron diseases, and amyotrophic lateral sclerosis 1991 ·Annals of Neurology ·David S. Younger, Lewis P. Rowland, N. Latov, Arthur P. Hays, Dale J. Lange, William H. Sherman, Giorgio Inghirami, (unknown), Dan Knowles, James F. Powers, James R. Miller, Michael R. Fetell, Robert E. Lovelace	95
19	Intratumor administration of beta-interferon in recurrent malignant gliomas. A phase I clinical and laboratory study 1990 ·Cancer ·Michael R. Fetell, Edgar M. Housepian, Martin W. Oster, (unknown), Michael B. Sisti, Stephen Marcus, Paul B. Fisher	28
20	Debrancher deficiency: Neuromuscular disorder in 5 adults 1979 ·Annals of Neurology ·Salvatore DiMauro, (unknown), Arthur Hays, Abraham B. Eastwood, (unknown), Marcelo R. Olarte, (unknown), Allen D. Roses, Michael R. Fetell, (unknown), Lawrence Z. Stern	125

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact